Perspective Therapeutics (CATX) Profit After Tax (2010 - 2026)

Perspective Therapeutics has disclosed Profit After Tax across 17 years of filings, most recently posting -$26.8 million for Q2 2026.

• In Q2 2026, Profit After Tax fell 24.67% year-over-year to -$26.8 million; the TTM figure through Jun 2026 stood at -$116.4 million (down 22.62% YoY), while the FY2025 annual figure was -$103.1 million, down 30.07% from the prior year.
• Profit After Tax came in at -$26.8 million for Q2 2026 at Perspective Therapeutics, down from -$26.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$371000.0 in Q1 2023 to a low of -$40.2 million in Q4 2024.
• Average Profit After Tax over 5 years is -$17.3 million, with a median of -$14.1 million recorded in 2022.
• Year-over-year, Profit After Tax surged 72.46% in 2023 and tumbled 3211.05% in 2024.
• Over 5 years, Profit After Tax stood at -$13.0 million in 2022, then slumped by 90.01% to -$24.7 million in 2023, then slumped by 62.79% to -$40.2 million in 2024, then advanced by 6.67% to -$37.5 million in 2025, then rose by 28.55% to -$26.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$26.8 million in Q2 2026, -$26.2 million in Q1 2026, and -$37.5 million in Q4 2025.